Phospho-NTRK1 (Tyr757) Antibody

What is NTRK1 (TrkA) and why is phosphorylation at Tyr757 significant?

NTRK1 (neurotrophic receptor tyrosine kinase 1), also known as TrkA, is a membrane-bound receptor encoded by the NTRK1 gene that primarily functions in the nervous system. This receptor is a high-affinity binding partner for nerve growth factor (NGF), which serves as its primary ligand . Upon NGF binding, NTRK1 undergoes homodimerization, leading to autophosphorylation at several tyrosine residues, including Tyr757.

Phosphorylation at Tyr757 is particularly significant because:

• It represents an activated state of the receptor

• It mediates downstream signaling through PLCγ pathways

• It contributes to cellular processes including differentiation and survival of sympathetic and nervous neurons

The functional significance of this phosphorylation site lies in its role in signal transduction. When phosphorylated, NTRK1 recruits and activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1, which regulate distinct overlapping signaling cascades driving cell survival and differentiation .

What are the key specifications of commercially available Phospho-NTRK1 (Tyr757) Antibodies?

Based on analysis of multiple vendor datasheets, Phospho-NTRK1 (Tyr757) Antibodies have the following typical specifications:

How should researchers design experiments to validate Phospho-NTRK1 (Tyr757) Antibody specificity?

A methodological approach to validating antibody specificity should include:

• Knockout/knockdown validation:

  • Utilize NTRK1 knockout mice tissues as negative controls to confirm signal absence

  • Compare with wild-type tissues showing positive signal

• Peptide competition assays:

  • Pre-incubate antibody with blocking peptide (phosphorylated peptide used as immunogen)

  • In valid antibodies, this should eliminate or significantly reduce signal in IHC or WB

• Phosphatase treatment controls:

  • Treat one set of samples with lambda phosphatase prior to immunoblotting

  • Signal should be absent in phosphatase-treated samples if antibody is phospho-specific

• Cross-validation with other methods:

  • Correlate antibody signal with known NTRK1 expression patterns from in situ hybridization data

  • Compare results with alternative antibodies targeting different epitopes of NTRK1

As demonstrated in search result , immunohistochemical analysis of paraffin-embedded human brain tissue showed positive staining with Phospho-NTRK1 (Tyr757) antibody, while the same antibody preincubated with blocking peptide showed no signal, confirming specificity.

How can Phospho-NTRK1 (Tyr757) Antibody be integrated into phospho-protein array technologies?

Phospho-protein arrays represent a powerful tool for analyzing the phosphorylation profiles of receptor tyrosine kinases, including NTRK1. When incorporating Phospho-NTRK1 (Tyr757) Antibody into such arrays:

• Array preparation methodology:

  • Arrays typically consist of nitrocellulose membranes with antibodies spotted in duplicate

  • Each membrane should include positive reference spots and negative controls

• Sample processing protocol:

  • Tissue lysates are applied to the membrane where both phosphorylated and unphosphorylated proteins bind to respective antibodies

  • Phosphorylated proteins are detected using pan-anti-phospho-tyrosine antibody conjugated with HRP

• Signal normalization considerations:

  • Include reference standards of known phosphorylation levels

  • Normalize signal intensity to total protein content in the sample

  • Compare phosphorylation patterns across multiple samples or conditions

• Data analysis approach:

  • Quantify signal intensity using densitometry software

  • Apply appropriate statistical methods for comparing phosphorylation levels between samples

  • Consider multivariate analysis for correlating phosphorylation patterns with biological outcomes

When utilizing phospho-protein arrays for clinical applications, be aware that these arrays "were made for research purposes on human biological samples" but have been successfully used "to profile various tumor types" and can be valuable for "personalized clinical medicine" .

What methodological considerations should be addressed when studying NTRK1 signaling pathways using phospho-specific antibodies?

When investigating NTRK1 signaling using Phospho-NTRK1 (Tyr757) Antibody, researchers should consider:

• Temporal dynamics of phosphorylation:

  • NGF treatment induces rapid phosphorylation of NTRK1

  • Design time-course experiments (5, 15, 30, 60 minutes) after NGF stimulation

  • Different phosphorylation sites may have distinct temporal patterns

• Integration with other signaling pathways:

  • NTRK1 activates multiple downstream pathways including MAPK, PI3K/AKT, and PKC

  • Use phospho-antibodies against key nodes in these pathways (e.g., phospho-ERK, phospho-AKT)

  • Consider pathway crosstalk in experimental design and data interpretation

• Correlation with functional outcomes:

  • Phosphorylation at Tyr757 regulates cell differentiation and survival

  • Design parallel assays to measure biological outcomes (neurite outgrowth, cell survival)

  • Correlate phosphorylation status with phenotypic changes

• Technical controls to include:

  • Stimulation with known NTRK1 activators (NGF) as positive control

  • Treatment with NTRK1 inhibitors as negative control

  • Comparison of phosphorylation across multiple tyrosine sites (Y496, Y676, Y680, Y681, Y757, Y791)

Remember that "phosphorylation of Y496 and Y791 of TRKA, and the corresponding tyrosine residues in TRKB and TRKC, drives downstream signaling. Specifically, phosphorylated Y496 directly binds and activates the SHC-transforming protein (SHC) and fibroblast growth factor receptor substrate 2 (FRS2), whereas phosphorylated Y791 interacts directly with PLCɣ" .

How can researchers distinguish between wild-type NTRK1 and NTRK fusion proteins using phosphorylation site-specific antibodies?

Distinguishing between wild-type NTRK1 and fusion proteins requires a careful methodological approach:

• Molecular weight analysis:

  • Wild-type NTRK1 appears at ~87-140 kDa on Western blots

  • NTRK1 fusion proteins typically have different molecular weights depending on fusion partner

  • Use standard curve of molecular weight markers for accurate size determination

• Phosphorylation site pattern analysis:

  • Compare phosphorylation patterns using antibodies against multiple phosphorylation sites

  • NTRK fusions may show constitutive phosphorylation independently of ligand stimulation

  • Some fusion proteins may lack certain phosphorylation sites present in wild-type NTRK1

• Complementary detection methods:

  • Combine phospho-antibody detection with break-apart FISH testing

  • Use RT-PCR to confirm specific fusion transcripts

  • Consider RNA sequencing for unbiased fusion detection

• Control experiments:

  • Use cell lines with known NTRK1 fusion status as positive controls

  • Include samples with NTRK1 amplification (which can cause overexpression without fusion)

  • Compare phosphorylation patterns before and after TRK inhibitor treatment

It's important to note that "NTRK fusion-positive tumors arise from fusion of the NTRK1/2/3 genes with other genes, which results in abnormalities in the encoded TRK protein. The sustained activation of the mutated TRK or TRK fusion proteins triggers a permanent signaling cascade, and these proteins are a major driver of tumor growth and metastasis in patients with TRK fusion cancers" .

What are the challenges in interpreting immunohistochemical results for Phospho-NTRK1 (Tyr757) in neural tissues?

Neural tissues present unique challenges for phospho-NTRK1 detection:

• Regional expression heterogeneity:

  • NTRK1 expression is highly localized to specific brain regions

  • Compare results with known expression patterns in "regions with known Ntrk1 expression, such as the striatum and basal forebrain"

  • Validate signals against "the characteristic expression pattern of Ntrk1 in the paraventricular thalamic nucleus (PVT)"

• Technical considerations for neural tissue processing:

  • Optimize fixation protocols to preserve phospho-epitopes (brief fixation in 4% PFA)

  • Use antigen retrieval methods specific for phospho-epitopes in neural tissues

  • Consider post-mortem interval effects on phosphorylation status

• Validation strategies for neural tissue:

  • Use NTRK1 knockout mice as negative controls

  • Compare with in situ hybridization data for NTRK1 mRNA expression

  • Validate with multiple antibodies targeting different phosphorylation sites

• Interpretation guidelines:

  • Expect high expression in "the striatum, caudate putamen, olfactory tubercle, globus pallidus, piriform cortex, nucleus accumbens, the horizontal and vertical limbs of the diagonal band of Broca, ventral tegmental nucleus, and medial vestibular nucleus"

  • Minimal signal expected in "the hippocampus and entorhinal cortex"

  • Distinguish between neuronal cell body and neuropil staining

For optimal validation, researchers should follow the approach described in search result , where "the utility of commercial antibodies for Ntrk1 using western blotting in brain lysates from Ntrk1 knockout mice" was tested, and the antibodies that "showed specificity in western blotting for immunohistochemistry applications in the adult mouse brain" were identified.

What methodological approaches can resolve contradictory results when using Phospho-NTRK1 (Tyr757) Antibody?

When faced with contradictory results using Phospho-NTRK1 (Tyr757) Antibody, consider these troubleshooting approaches:

• Antibody validation reassessment:

  • Repeat peptide competition assays with phospho and non-phospho peptides

  • Test antibody on NTRK1-null and NTRK1-overexpressing cell lines

  • Compare results from multiple antibody sources/lots

• Sample preparation optimization:

  • Evaluate phosphatase inhibitor effectiveness in sample preparation

  • Test multiple fixation protocols to preserve phospho-epitopes

  • Compare fresh vs. frozen vs. FFPE sample preparation methods

• Technical factors evaluation:

  • Optimize antibody concentration through titration experiments (try 1:50-1:300 range for IHC)

  • Test multiple detection systems (HRP vs. fluorescent secondary antibodies)

  • Evaluate blocking reagents for reduction of non-specific binding

• Multi-method validation approach:

  • Confirm results using alternative methods (WB, IF, IHC)

  • Correlate antibody signal with functional assays of NTRK1 activity

  • Consider mass spectrometry analysis of phosphorylation sites

• Experimental design considerations:

  • Include appropriate positive and negative controls in each experiment

  • Design time-course experiments to capture dynamic phosphorylation events

  • Consider context-dependent phosphorylation (cell type, stimulation conditions)

Remember that phosphorylation is a dynamic process, and contradictory results may reflect real biological variation rather than technical issues.

How can Phospho-NTRK1 (Tyr757) Antibody be used in screening potential TRK inhibitor therapies?

Phospho-NTRK1 (Tyr757) Antibody offers valuable methodological approaches for screening TRK inhibitor therapies:

• Cell line-based screening protocol:

  • Establish dose-response curves using cell lines with NTRK1 expression or fusion

  • Measure phospho-NTRK1 levels before and after inhibitor treatment

  • Correlate phosphorylation inhibition with cell proliferation/survival assays

• Patient-derived sample assessment:

  • Use phospho-protein arrays to profile tyrosine kinase activity in tumor samples

  • Compare phosphorylation patterns across multiple patient samples

  • Identify patients likely to respond to TRK inhibitors based on phosphorylation status

• Combinatorial therapy evaluation:

  • Assess phospho-NTRK1 inhibition when TRK inhibitors are combined with other therapeutic agents

  • Monitor escape mechanisms through reactivation of phosphorylation

  • Track duration of phosphorylation inhibition over time

• Resistance mechanism investigation:

  • Compare phospho-NTRK1 patterns in treatment-naïve vs. resistant samples

  • Monitor development of resistance by sequential sampling and phospho-profiling

  • Correlate emergence of resistance mutations with changes in phosphorylation patterns

This approach is relevant because "the treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rates (>75%), regardless of tumour histology" .

What strategies should researchers employ when investigating NTRK1 phosphorylation in tumors with gene amplification versus fusion?

Distinguishing phosphorylation patterns in NTRK1 amplification versus fusion requires tailored methodological approaches:

• Comprehensive molecular profiling:

  • Combine phospho-antibody detection with FISH testing to determine fusion vs. amplification status

  • Use NTRK1 break-apart probes to detect fusion events

  • Quantify copy number to identify amplification

• Phosphorylation pattern analysis:

  • Compare constitutive vs. ligand-dependent phosphorylation patterns

  • Assess multiple phosphorylation sites simultaneously

  • Evaluate downstream signaling activation patterns which may differ between fusion and amplification

• Experimental design considerations:

  • Include cell line models with known NTRK1 amplification or fusion status

  • Test phosphorylation response to TRK inhibitors (may differ between fusion and amplification)

  • Evaluate dose-response relationships for inhibition of phosphorylation

• Methodological approach for clinical samples:

  • Perform sequential staining on serial sections using pan-TRK and phospho-specific antibodies

  • Correlate staining intensity with gene copy number data

  • Compare with RNA-seq data to confirm fusion transcripts

How can phosphorylation site-specific antibodies help elucidate resistance mechanisms to TRK inhibitor therapy?

Phospho-specific antibodies provide valuable tools for investigating resistance mechanisms:

• Temporal monitoring protocol:

  • Collect sequential samples during treatment and at progression

  • Monitor phosphorylation status at multiple NTRK1 sites (Tyr496, Tyr676/680/681, Tyr757, Tyr791)

  • Correlate changes in phosphorylation patterns with clinical response

• Bypass pathway identification:

  • Assess phosphorylation of alternative RTKs that may compensate for NTRK1 inhibition

  • Use phospho-protein arrays to examine multiple RTKs simultaneously

  • Identify novel phosphorylation sites that emerge during resistance development

• Mutation-specific phosphorylation analysis:

  • Compare phosphorylation patterns between wild-type and mutated NTRK1

  • Focus on solvent front mutations that frequently emerge during TRK inhibitor therapy

  • Assess differential inhibition of phosphorylation by first vs. second-generation TRK inhibitors

• Functional correlation approaches:

  • Establish cell line models with acquired resistance to TRK inhibitors

  • Compare phosphorylation patterns with parental sensitive lines

  • Validate findings using patient-derived samples pre- and post-resistance

This methodological approach is relevant because "despite durable disease control in many patients, advanced-stage NTRK fusion-positive cancers eventually acquire resistance to these agents" , necessitating detailed understanding of the underlying mechanisms.

What are the optimal sample preparation protocols for preserving phospho-epitopes when using Phospho-NTRK1 (Tyr757) Antibody?

Preserving phospho-epitopes requires careful sample handling:

• Tissue sample preparation protocol:

  • Harvest tissues rapidly and process immediately to minimize phosphatase activity

  • Use phosphatase inhibitor cocktails in all extraction buffers

  • Flash-freeze samples in liquid nitrogen if immediate processing isn't possible

• Fixation optimization for IHC:

  • Use brief fixation (4-8 hours) with fresh 4% paraformaldehyde

  • Avoid over-fixation which can mask phospho-epitopes

  • Consider alcohol-based fixatives which may better preserve phosphorylation

• Protein extraction methodology:

  • Use lysis buffers containing both phosphatase inhibitors (sodium fluoride, sodium orthovanadate) and protease inhibitors

  • Maintain samples at 4°C during processing

  • Avoid repeated freeze-thaw cycles which can degrade phospho-epitopes

• Antigen retrieval optimization:

  • Test multiple antigen retrieval methods (citrate, EDTA, Tris-EDTA)

  • Optimize pH and heating conditions for phospho-epitope recovery

  • Include positive control tissues with known phospho-NTRK1 expression

For IHC applications, vendors recommend "immunohistochemistry: 1/100 - 1/300" dilutions, and researchers should validate optimal conditions for their specific samples and detection systems.

What experimental controls are essential when using Phospho-NTRK1 (Tyr757) Antibody for quantitative analysis?

Rigorous control design is critical for quantitative phospho-NTRK1 analysis:

• Positive controls:

  • Cell lines treated with NGF to stimulate NTRK1 phosphorylation

  • Brain regions with known high NTRK1 expression (striatum, basal forebrain)

  • Recombinant phosphorylated NTRK1 protein (for Western blot standardization)

• Negative controls:

  • NTRK1 knockout tissues or cells

  • Samples treated with lambda phosphatase to remove phosphorylation

  • Primary antibody omission controls

• Specificity controls:

  • Peptide competition with phosphorylated and non-phosphorylated peptides

  • Comparison with other phospho-NTRK1 antibodies targeting different sites

  • Signal validation with multiple detection methods

• Quantification standards:

  • Include calibration standards with known quantities of phosphorylated protein

  • Perform standard curve analysis for each experiment

  • Use housekeeping proteins or total NTRK1 for normalization

• Technical replicates:

  • Perform at minimum triplicate technical replicates

  • Include biological replicates from independent samples

  • Apply appropriate statistical analyses for quantitative comparisons

When processing data, researchers should be aware that "phospho-protein arrays used in experiments are based on analysis of tissue samples on nitrocellulose membranes, where specific antibodies against selected kinases are spotted in duplicate. In addition to these antibodies, each membrane contains three positive reference double spots and one negative control containing PBS only" .